 |
|
Aspirin, Postmenopausal Hormones, and C-Reactive Protein
Arch Intern Med. 2002;162:480-481.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Most oral preparations of postmenopausal hormones (PMHs) increase levels
of C-reactive protein (C-RP), a sensitive marker of inflammation, within about
4 weeks of initiation of therapy.1-3
This increase is observed in patients who are given either estrogen alone
or estrogen in combination with a progestin, which has now become the most
common preparation of PMH used. These data derive from observational studies
and randomized trials of apparently healthy women suggesting that the increase
is not attributable to atherosclerotic burden or other risk factors for cardiovascular
disease or to other inflammatory disorders.4
Elevated levels of C-RP predict increased risks of subsequent cardiovascular
events in both men and women.5-6
The mechanisms by which this occurs are not clear. C-reactive protein may
be a marker for predicting an increased risk of events or may have some direct
proinflammatory and atherogenic properties. It is present in atherosclerotic
plaques. Furthermore, recent data suggest that C-RP . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Aspirin Use, Dose, and Clinical Outcomes in Postmenopausal Women With Stable Cardiovascular Disease: The Women's Health Initiative Observational Study
Berger et al.
Circ Cardiovasc Qual Outcomes 2009;2:78-87.
ABSTRACT
| FULL TEXT
Endogenous Salicylates, Aspirin, and Inflammation
Paterson and Lawrence
Arch Intern Med 2002;162:1531-1532.
FULL TEXT
|
